ReviewAntimicrobial agents and chemotherapy2022
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Review in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Ceftriaxone for methicillin-susceptibleAnnals of medicine · 2026Pooled it
- The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused byOpen forum infectious diseases · 2025Trial
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Current practices and challenges in the management of acute bacterial skin and skin structure infections (ABSSSI): results from an Italian multicentre survey with expert discussion.JAC-antimicrobial resistance · 2026Article
- Drug-Resistant Gram-Positive Cocci as Etiological Factors of Cardiac Implantable Electronic Device Infections-Data from the EXTRACT Registry.Antibiotics (Basel, Switzerland) · 2026Article
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
- Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report.Respiratory medicine case reports · 2026Article
- Inpatient versus outpatient management of community-acquired acute skin and soft tissue infections. Clinical outcomes and factors associated with eligibility for early discharge.BMC infectious diseases · 2025Article
- Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials.The Journal of antimicrobial chemotherapy · 2025Article
- Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?Heliyon · 2025Article
- Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection.Pharmaceutics · 2024Article
- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.Nature reviews. Microbiology · 2024Review
- Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review.The Journal of antimicrobial chemotherapy · 2024Review
- Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.Infectious diseases and therapy · 2024Article
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?Pathogens (Basel, Switzerland) · 2024Review
- Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods.Journal of mass spectrometry and advances in the clinical lab · 2024Review
- [Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Current approach to skin and soft tissue infections. Thinking about continuity of care.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft tissue infections, their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as bloodstream and bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and avoidance of long-term intravascular catheter access are desirable or when multidrug-resistant bacteria are suspected. This review describes the current evidence for the use of oritavancin and dalbavancin in the treatment of invasive infections, as well as the hurdles that are preventing their optimal use. Moreover, this review discusses the current knowledge gaps that need to be filled to understand the potential role of LGPs in highly needed clinical scenarios and the ongoing clinical studies that aim to address these voids in the upcoming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.